Literature DB >> 29299418

Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?

Alejandro Navarro1, Enriqueta Felip1.   

Abstract

Entities:  

Year:  2017        PMID： 29299418      PMCID： PMC5750169          DOI： 10.21037/tlcr.2017.10.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  14 in total

1.  PD-L1 expression in small cell neuroendocrine carcinomas.

Authors:  Anne M Schultheis; Andreas H Scheel; Luka Ozretić; Julie George; Roman K Thomas; Thorsten Hagemann; Thomas Zander; Jürgen Wolf; Reinhard Buettner
Journal:  Eur J Cancer       Date:  2015-01-09       Impact factor: 9.162

2.  Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.

Authors:  Patrick A Ott; Elena Elez; Sandrine Hiret; Dong-Wan Kim; Anne Morosky; Sanatan Saraf; Bilal Piperdi; Janice M Mehnert
Journal:  J Clin Oncol       Date:  2017-08-16       Impact factor: 44.544

3.  Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline.

Authors:  Charles M Rudin; Nofisat Ismaila; Christine L Hann; Narinder Malhotra; Benjamin Movsas; Kim Norris; M Catherine Pietanza; Suresh S Ramalingam; Andrew T Turrisi; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

4.  Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.

Authors:  Hidenobu Ishii; Koichi Azuma; Akihiko Kawahara; Kazuhiko Yamada; Yohei Imamura; Takaaki Tokito; Takashi Kinoshita; Masayoshi Kage; Tomoaki Hoshino
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

Review 5.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

6.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

7.  Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Authors:  Martin Reck; Alexander Luft; Aleksandra Szczesna; Libor Havel; Sang-We Kim; Wallace Akerley; Maria Catherine Pietanza; Yi-Long Wu; Christoph Zielinski; Michael Thomas; Enriqueta Felip; Kathryn Gold; Leora Horn; Joachim Aerts; Kazuhiko Nakagawa; Paul Lorigan; Anne Pieters; Teresa Kong Sanchez; Justin Fairchild; David Spigel
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

8.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).

Authors:  Glen J Weiss; Jordan Waypa; Lisa Blaydorn; Jessica Coats; Kayla McGahey; Ashish Sangal; Jiaxin Niu; Cynthia A Lynch; John H Farley; Vivek Khemka
Journal:  Br J Cancer       Date:  2017-06-06       Impact factor: 7.640
View more
  4 in total

Review 1.  [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].

Authors:  Di Zhang; Jiaqi Huang; Chufeng Zhang; Yan Guan; Qisen Guo
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-06-20

Review 2.  [Immune Characteristics of Small Cell Lung Cancer].

Authors:  Yan Zhu; Shikai Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-10-20

Review 3.  Splicing Variants, Protein-Protein Interactions, and Drug Targeting in Hutchinson-Gilford Progeria Syndrome and Small Cell Lung Cancer.

Authors:  Bae-Hoon Kim; Tae-Gyun Woo; So-Mi Kang; Soyoung Park; Bum-Joon Park
Journal:  Genes (Basel)       Date:  2022-01-18       Impact factor: 4.096

4.  Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.

Authors:  Changxia Shao; Jinghua He; Sumesh Kachroo; Fan Jin
Journal:  Cancer Med       Date:  2019-10-31       Impact factor: 4.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.